San Jose-based biotech firm Allay Therapeutics has raised US$57.5 million in a series D financing round led by Lightstone Ventures and Temasek’s biotech platform, ClavystBio.

Existing investors NEA and Vertex Growth, along with new backers IPD Capital, EDBI, and Maruishi Pharmaceutical, also participated.

HSBC contributed through venture debt financing.

The funds will support the Phase 2b registration trial of Allay’s investigational analgesic, ATX101, aimed at managing post-surgical pain in total knee replacement patients.

The trial started in February 2025, includes 200 participants across multiple US sites, and results are expected in Q4 2025.

The company plans to initiate a Phase 3 trial in 2026.

🔗 Source: Allay Therapeutics

🧠 Food for thought

1️⃣ Growing investor interest reflects expanding pain management market

Allay’s substantial $57.5 million Series D financing comes amid significant growth in the broader pain management sector, which is projected to expand from $84.6 billion in 2023 to $109.9 billion by 2028, representing a 5.4% CAGR 1.

The funding round’s strong participation from both existing and new investors reflects the market’s recognition of post-surgical pain management as a critical healthcare need with substantial commercial potential.

The company’s focus on total knee arthroplasty (TKA) addresses a significant market, particularly as osteoarthritis affects 7.6% of the global population with projections suggesting a 60-100% increase by 2050 2.

Maruishi Pharmaceutical’s expansion of its license territory to include South Korea and Taiwan, beyond the original Japan agreement, signals international confidence in Allay’s technology and growth potential in Asian markets.

2️⃣ Non-opioid alternatives gaining momentum amid shifting regulatory landscape

Allay’s development of ATX101 aligns with the significant shift in pain management protocols, as reflected in the CDC’s 2022 updated guidelines that emphasize non-opioid therapies as first-line treatments for pain 3.

The company’s breakthrough therapy designation from the FDA highlights the regulatory recognition of novel non-opioid approaches, especially as chronic pain affects approximately 100 million people in the U.S. alone 4.